21 CFR Part 111: What Brands Need to Know
Recorded sources last checked between August 29, 2026 and September 29, 2026. 22 of 22 recorded claims have no open issue recorded. Source check due February 28, 2027.
By Greg Huang, founder since 2009 in the dietary supplement and nutrition industry
Reviewed by Dr. James Pendleton, ND, licensed primary care physician, 20+ years in naturopathic medicine
The short answer
If you sell dietary supplements in the United States, the manufacturers you work with must comply with 21 CFR Part 111. This guide explains what Part 111 requires in plain language, without regulatory jargon or legalese. If you are new to manufacturing regulations entirely, start with our primer on what GMPs are and come back here for the Part 111 specifics.
Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.
What Part 111 Is
21 CFR Part 111 is the FDA regulation that establishes Current Good Manufacturing Practice (cGMP) for dietary supplements. It was finalized in 2007 and applies, operation by operation, to companies that manufacture, package, label, or hold dietary supplements sold in the United States. The one narrow carve-out: under 21 CFR 111.1(b), the holding requirements do not apply to a retail establishment holding product solely for direct sale to individual consumers (a retailer's warehouse does not qualify for that exemption).
The regulation covers the entire manufacturing process, from receiving raw materials to shipping finished products. Its purpose is to ensure that dietary supplements are produced consistently, meet quality standards, and contain what their labels say they contain.
Who It Applies To
Part 111 applies, operation by operation, to domestic and foreign facilities that manufacture, package, label, or hold dietary supplements for sale in the U.S. (retail establishments holding product solely for direct sale to individual consumers are exempt from the holding requirements under 21 CFR 111.1(b)). Facilities it covers include:
- Contract manufacturers (CMs) who produce supplements for brands
- Co-packers who package or label products
- Warehouses and distribution centers that hold dietary supplements
- Brands that manufacture their own products in-house
As a brand, Part 111 obligations attach to the operations you actually perform: if your own business packages, relabels, warehouses, or distributes product (not just manufactures), the subparts covering those operations apply to you directly. A brand that outsources everything still carries responsibility for choosing compliant manufacturers, and FDA holds own-label distributors accountable for their supply chain. If your CM isn't cGMP-compliant, your products are non-compliant.
What Part 111 Covers
Part 111 is organized into sixteen subparts, labeled A through P. In plain language, they group into these core operational areas.
Personnel
People who work in supplement manufacturing must be qualified, with the education, training, or experience to perform their assigned functions, and must follow hygienic practices. The regulation requires you to identify who is responsible for quality control operations, and each person doing that work must be qualified for it.
Physical Plant and Grounds
Manufacturing facilities must be designed and maintained to prevent contamination. This covers building design, water systems, plumbing, sewage, pest control, cleaning, and sanitation. To prevent contamination and mixups, facilities must use separate or defined areas, or other control systems such as computerized inventory controls, for listed operations like receiving, holding, and manufacturing.
Equipment and Utensils
All equipment used in manufacturing must be appropriate for its intended use, maintained in a clean and sanitary condition. Instruments and controls must be calibrated before first use and then either at the frequency their manufacturer specifies or at routine intervals as needed to keep them accurate. Automated, mechanical, and electronic equipment must be shown capable of operating within the process limits and routinely calibrated, inspected, or checked.
Production and Process Control System
Manufacturers must have a written production and process control system. This includes master manufacturing records (the recipe), batch production records (what actually happened), and procedures for every step from receiving materials to releasing finished product.
Production and In-Process Controls
This is the detailed "how" of manufacturing. It covers receiving and inspecting raw materials, identifying and holding components, producing supplements according to the master record, sampling and testing during production, handling reprocessing, and managing rejected materials.
Laboratory Operations
Testing requirements for raw materials and finished products. Labs must use scientifically valid methods, maintain proper records, and test for identity, purity, strength, and composition.
Holding and Distribution
Requirements for storing components and finished products under appropriate conditions (temperature, humidity, light). Distribution records must be maintained to enable product recalls when necessary.
Records and Recordkeeping
Detailed requirements for what records must be kept and for how long (21 CFR 111.605): one year past the shelf-life date when the product carries one, otherwise two years beyond the date of distribution of the last batch associated with those records. This includes batch records, lab results, complaint files, and returned product records.
Common FDA Inspection Observations
FDA publishes its warning letters and, by fiscal year, spreadsheets of the regulations cited on Form 483 inspection observations. A Form 483 records what an investigator observed; it is not a final agency finding of a violation. In the fiscal 2025 data, the Part 111 requirements most frequently cited on Form 483s include:
- Failure to establish product specifications. Not defining what the finished product should contain, including identity, purity, strength, and composition limits.
- Failure to test components for identity before use. Using raw materials without confirming they are what the supplier says they are.
- Failure to establish and follow written production procedures. No master manufacturing records, or manufacturing that deviates from written procedures without documentation.
- Inadequate testing of finished products. Releasing products without testing for identity, purity, strength, composition, and contamination.
- Inadequate batch production records. Incomplete documentation of what happened during production: missing times, temperatures, quantities, or personnel records.
- Failure to handle product complaints. No written procedures to review and investigate product complaints.
Source: FDA's fiscal 2025 Form 483 observation spreadsheet; FDA warning letters are publicly available on the FDA website.
What This Means for Brands
If you're a brand working with contract manufacturers, Part 111 compliance should be a baseline requirement, not a bonus. Here's what you should do:
- Confirm your CM is FDA registered and can provide their registration number
- Ask for their most recent third-party cGMP audit report
- Request documentation of their production and process control system
- Verify they test raw materials for identity and finished products for specifications
- Review their complaint handling and adverse event reporting procedures
- Include cGMP compliance requirements in your manufacturing agreement
For a complete framework on evaluating manufacturers, see our guide to evaluating supplement manufacturers.
Greg Huang, founder since 2009 in the dietary supplement and nutrition industry
Founder of Inventory Ready. Previously founded and operated multiple consumer brands in the dietary supplement and nutrition industry since summer 2009.
Concepts Covered
Stay informed
Regulatory updates, new manufacturer assessments, and tool launches.
Disclaimer: This guide is educational content based on publicly available FDA regulations and enforcement records. It is not legal or regulatory advice. The full text of 21 CFR Part 111 is available on the Electronic Code of Federal Regulations. Consult qualified regulatory counsel for compliance guidance. See our Terms of Service.
Primary sources
The sourced claims in this guide are grounded in the following primary references. The guide's source manifest maps each claim to its source and verification date.
- FDA cGMP Final Rule, 72 FR 34752 (June 25, 2007), DATES: compliance June 25, 2008; June 25, 2009 for businesses with fewer than 500 but 20 or more full-time equivalent employees; June 25, 2010 for fewer than 20
- 21 CFR 111.75
- 21 CFR 111.320
- 21 CFR 111.12(b) (identify who is responsible for quality control)
- 21 CFR 111.105
- 21 CFR 111.605(a), quoted verbatim: 'You must keep written records required by this part for 1 year past the shelf life date, if shelf life dating is used, or 2 years beyond the date of distribution of the last batch of dietary supplements associated with those records.'
- 21 CFR Part 111 heading (eCFR)
- 21 U.S.C. 342(g)(1)
- FDA, FDA Form 483 Frequently Asked Questions
- FDA warning letter to a dietary supplement manufacturer citing Part 111 (September 10, 2025)
- FDA Inspection Observations, FY2025 data set (Foods sheet)